Comparison of systemic conditions at diagnosis between central retinal vein occlusion and branch retinal vein occlusion

Bum-Joo Cho, So Hyun Bae, Sang Min Park, Min Chul Shin, In Won Park, Ha Kyoung Kim, Soonil Kwon*

1 Department of Ophthalmology, Hallym University College of Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea, 2 Department of Ophthalmology, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, Korea, 3 Cardiovascular Center, Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, Korea, 4 Department of Ophthalmology, Hallym University College of Medicine, Chuncheon Sacred Heart Hospital, Chuncheon, Korea

* magicham@hallym.or.kr

Abstract

Objective
To compare systemic conditions at the time of diagnosis between patients with central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

Design
This study included patients diagnosed with CRVO or BRVO between February 2009 and August 2017 at three branch hospitals of Hallym University Medical Center. Demographic and anthropometric variables, systemic comorbidity profiles, and laboratory findings at diagnosis were collected from a clinical data warehouse system, and were compared between the CRVO and BRVO groups.

Result
Four hundred and seventeen patients with CRVO and 1,511 patients with BRVO were included. The mean age was 61.8 ± 13.9 years, which was comparable between two groups (P = .332). Female proportion was higher in the BRVO group (55.0%) than in the CRVO group (48.0%; P = .013). Diabetes mellitus (P = .017) and chronic kidney disease (P = .004) were more prevalent in the CRVO group. Serum homocysteine level was abnormally high in 23.5% of CRVO patients and in 8.4% of BRVO patients (P < .001). Blood urea nitrogen and serum creatinine levels were abnormally elevated in more subjects with CRVO (P = .002).

Conclusion
CRVO is associated with higher prevalence of diabetes mellitus and chronic kidney disease, as well as with elevated serum homocysteine level. These results might suggest a difference between the pathophysiology of CRVO and BRVO.
Introduction

Retinal vein occlusion (RVO) is the most common retinal vascular disease after diabetic retinopathy, and it is one of the major causes of visual impairment worldwide [1, 2]. It is categorized as central RVO (CRVO) and branch RVO (BRVO) depending on the site of closure, and these two subtypes differ with regard to the clinical course and visual prognosis [2, 3]. Of note, the pathogenesis of RVO is still not completely understood, and it remains unclear whether the mechanisms underlying CRVO and BRVO are similar [4].

To reveal the pathophysiology of different types of RVO, investigation of systemic conditions combined with RVO may provide useful clues. Thus far, the development of RVO has been associated with obesity, smoking, and hemorheological factors [4–6]. Systemic conditions have been also reported as risk factors, such as hypertension, diabetes, dyslipidemia, and other cardiovascular diseases [7]. Notably, BRVO was associated with a higher prevalence of arterial hypertension, peripheral vascular disease, and atherosclerosis, compared to CRVO [8–10]. Genetic profile and some laboratory test results such as uric acid, glucose, and anti-nuclear antibody were also different between patients with BRVO and those with CRVO [11, 12]. Nevertheless, direct comparison on both systemic comorbidities and comprehensive laboratory test results between BRVO and CRVO patients in the same institution is limited yet, especially for Asian ethnics.

In this study, we aimed to investigate differences in systemic conditions including various laboratory results at diagnosis between CRVO and BRVO. To explore the large database of three hospitals collecting clinical information of patients with each type of RVO, we used the common integrated clinical data warehouse (CDW) system of the hospitals, which is an electronic data repository of patient and provider information [13]. This is one of the largest study on the association of systemic diseases with BRVO and CRVO in Asians. The findings of this study are expected to provide insight into the differences in the pathogenesis of CRVO and BRVO.

Materials and methods

Study population

The dataset analyzed in the current study was acquired from the common integrated electronic CDW system of Hallym University Medical Center (HUMC) [14]. The common CDW system of HUMC collects and stores extensive electronic medical data including medical records, laboratory results, physical measurements, diagnostic and therapeutic history, and medication history, over a period of 10 years from the five branch hospitals of HUMC [14]. We accessed the CDW system and investigated the medical data of patients who were newly diagnosed with RVO between February 2009 and August 2017 at any of three branch hospitals of HUMC: Hallym University Sacred Heart Hospital (HSHH), Kangnam Sacred Heart Hospital (KSHH), and Chuncheon Sacred Heart Hospital (CSHH). This study was approved by the institutional review board of HUMC, and all protocols were in accordance with the tenets of the Declaration of Helsinki. Informed consent was waived because of the retrospective nature of the study and the de-identification by the CDW system before we access the database.

We first identified patients diagnosed with RVO (Korean Standard Classification of Diseases (KCD) code H34.8, corresponding to the International Classification of Diseases, 9th Revision, Clinical Modification (ICD-9-CM) code 362.35 for CRVO or 362.36 for BRVO) during the period mentioned above. If a patient developed both types of RVO during the clinical course, the initially occurring type was included. Next, to ensure the inclusion of patients with new episodes only, we verified the presence of a previous RVO diagnosis by reviewing the visit data for all eligible patients, beginning from the earliest period for which medical records were available.
provided by the CDW system (January 2007 for HSHH, February 2008 for KSHH, and March 2007 for CSHH). We evaluated data pertaining to all visits made during ≥ 1 year before RVO diagnosis. All patients with a previous diagnosis of RVO were then excluded.

**Main outcome measures**

The data of study subjects were investigated with regard to the systemic conditions at the time of RVO diagnosis. The electronic CDW system of HUMC was used to derive data pertaining to the demographic characteristics of patients, underlying systemic comorbidities, physical measurements, and laboratory findings of blood tests and urine tests. For anthropometric values and laboratory findings, test results from 14 days before to 7 days after the diagnosis of RVO were selectively included for analysis. When two or more test results were available, values obtained at the date closest to the date of RVO diagnosis were selected. Systemic diseases diagnosed before RVO diagnosis were defined as underlying comorbidities.

Demographic characteristics included the patient’s sex and age at RVO diagnosis. Systemic comorbidities were investigated using the KCD code system. The prevalence rates of the 10 most common diseases in our RVO patients, including diabetes mellitus (DM), hypertension, ischemic heart disease (IHD), dyslipidemia, cerebral infarction, cerebral hemorrhage, arrhythmia, chronic kidney disease diseases (CKD), gastroduodenal ulcer or inflammation, and benign prostatic hyperplasia were compared between the two groups. The specific criteria for the diagnosis of systemic diseases are presented in S1 Table.

Physical measurements included height, weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), and the body mass index (BMI). The laboratory protocol for RVO included a complete blood count with differential [white blood cells, hemoglobin, hematocrit, platelet count, etc.]; blood coagulation-related test [activated partial thromboplastin time, prothrombin time (PT), and serum homocysteine]; a lipid profile [total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides]; a liver function test, including alanine transaminase and aspartate aminotransferase (AST) levels; blood urea nitrogen (BUN) measurement, and creatinine measurement. Because some laboratory test results were unobtainable for some patients, the tests of which results were available in more than 10% of the whole study participants were included in the analyses. The absolute values of laboratory findings and the proportion of subjects with abnormal findings were compared between the two groups.

**Statistical analyses**

The patients were assigned to a BRVO group and a CRVO group. Then, the outcome variables were compared between the groups. Continuous variables were expressed as means ± standard deviations, and categorical variables were expressed as the number and proportion of patients. Chi-square tests, Fisher’s exact tests, independent t-tests, and paired t-tests were used for statistical analyses. A P-value of < .05 was considered statistically significant. All statistical analyses were performed using R version 3.3.3 (The R Foundation for Statistical Computing, Vienna, Austria).

**Data availability**

Data supporting the findings of the current study are available from the corresponding author on reasonable request.

**Results**

In total, 1,928 patients with RVO were included: 753 patients were recruited from HSHH, 595 patients were from KSHH, and 580 patients were from CSHH. There was no difference in age,
the proportion of patients with CRVO, the proportion of male patients, and the BMI (\( P = .468 \), \( P = .424 \), \( P = .211 \), and \( P = .645 \), respectively) among the three hospitals. In the entire group, mean age at diagnosis was 61.8 ± 13.9 years and 897 (46.5%) subjects were male.

Among the entire group, 417 and 1,511 patients were diagnosed with CRVO and BRVO, respectively. The demographic characteristics of the patients are presented in Table 1. The mean age was 61.2 ± 16.7 years in the CRVO group and 62.0 ± 13.1 years in the BRVO group (\( P = .332 \)). The BRVO group had a significantly higher proportion of female patients than did the CRVO group (55.0% vs. 48.0%, respectively; \( P = .013 \)). DBP was significantly lower in patients with CRVO than in patients with BRVO (77.4 ± 16.8 mmHg vs. 84.5 ± 17.1 mmHg, respectively; \( P = .011 \)). There were no significant differences in the other variables, including height, weight, BMI, and SBP (\( P > .05 \) for all).

### Systemic comorbidities

Table 2 presents the systemic disease profile at the time of RVO diagnosis. Hypertension was the most common underlying disease (17.3% in CRVO and 15.2% in BRVO), followed by

### Table 1. Demographic characteristics of patients with branch retinal vein occlusion and those with central retinal vein occlusion.

|                  | CRVO  | BRVO  | \( P \)-value |
|------------------|-------|-------|---------------|
| **N**            | 417   | 1511  |               |
| **Values**       | 61.2 ± 16.7 | 62.0 ± 13.1 | .332*         |
| **Sex, Male (%)**| 417   | 1511  |               |
|                  | 217 (52.0%) | 680 (45.0%) | .013*         |
| **Height (cm)**  | 44    | 61    |               |
|                  | 160.8 ± 8.6 | 160.6 ± 9.1 | .879*         |
| **Weight (Kg)**  | 48    | 76    |               |
|                  | 62.4 ± 11.2 | 64.7 ± 11.5 | .293*         |
| **BMI (Kg/m\(^2\))** | 44    | 61    |               |
|                  | 23.8 ± 2.9 | 24.8 ± 3.5 | .124*         |
| **SBP (mmHg)**   | 56    | 130   |               |
|                  | 131.4 ± 29.0 | 138.0 ± 27.8 | .140*         |
| **DBP (mmHg)**   | 56    | 130   |               |
|                  | 77.4 ± 16.8 | 84.5 ± 17.1 | .011*         |

CRVO: central retinal vein occlusion, BRVO: branch retinal vein occlusion, BMI: body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure

*Independent t-test

**Pearson’s chi-square test

https://doi.org/10.1371/journal.pone.0220880.t001

### Table 2. Systemic comorbidities in patients with branch retinal vein occlusion and those with central retinal vein occlusion.

|                  | CRVO (\( N = 417 \)) | BRVO (\( N = 1511 \)) | \( P \)-value |
|------------------|-----------------------|------------------------|---------------|
| Hypertension     | 72 (17.3%)            | 229 (15.2%)            | .330*         |
| Diabetes mellitus| 42 (10.1%)            | 98 (6.5%)              | .017*         |
| Ischemic heart disease | 25 (6.0%) | 63 (4.2%) | .147*         |
| Dyslipidemia     | 22 (5.3%)             | 85 (5.6%)              | .877*         |
| Cerebral infarction | 10 (2.4%)  | 53 (3.5%)             | .331*         |
| Cerebral hemorrhage | 2 (0.5%)    | 10 (0.7%)             | 0.946\(^b\) |
| Arrhythmia       | 9 (2.2%)              | 38 (2.5%)              | 0.811*        |
| Chronic kidney disease | 18 (4.3%)  | 27 (1.8%)             | .004*         |
| Gastroduodenal ulcer or inflammation | 32 (7.7%) | 137 (9.1%) | .428*         |
| Benign prostatic hyperplasia | 18 (4.3%) | 50 (3.3%) | .402*         |

BRVO: branch retinal vein occlusion, CRVO: central retinal vein occlusion

*Pearson’s chi-square test

\(^b\)Fisher’s exact test

https://doi.org/10.1371/journal.pone.0220880.t002
DM. The CRVO group showed a higher prevalence of DM and CKD than did the BRVO group (10.1% vs. 6.5% for DM, \(P = .017\); 4.3% vs. 1.8% for CKD, \(P = .004\)). There was no significant difference in the prevalence rates of other comorbid diseases between the two groups.

Laboratory tests

Tables 3 and 4 show the laboratory findings of patients with BRVO and CRVO. The serum hemoglobin level was significantly lower in the CRVO group than in the BRVO group (13.3 g/dL vs. 13.7 g/dL, respectively; \(P = .025\)). The prothrombin time was also shorter in the CRVO group (\(P = .004\)). Other coagulation-related findings, including serum platelet count, were comparable between the groups (\(P > .05\) for all).

The blood homocysteine level (13.3 ± 6.9 umol/L vs. 11.0 ± 5.2 umol/L, \(P = .008\)) was significantly higher in patients with CRVO than in those with BRVO. The proportion of patients with serum homocysteine level beyond the normal range was 23.5% in the CRVO group and 8.4% in the BRVO group (\(P < .001\); Table 5). The serum glucose level was higher in the CRVO group than in the BRVO group (\(P = .023\)).

Serum AST was significantly higher in patients with BRVO than in those with CRVO (\(P = .001\)), but these values were within the normal range in both groups. The serum cholesterol levels were not different between two groups (\(P > .05\) for all). The CRVO group showed a higher proportion of neutrophils and a lower proportion of lymphocytes compared to the BRVO group (\(P = .004\) and \(P = .003\), respectively; Table 4). Other laboratory findings did not show any significant difference between the two groups (\(P > .05\)). Of note, patients with abnormally high level of serum BUN and creatinine were more prevalent in the CRVO group than in the BRVO group (\(P = .002\) for both; Table 5).

Of note, 26 (6.2%) of 417 patients with CRVO developed BRVO during follow-up and 17 (1.1%) of 1,511 BRVO patients developed CRVO during follow-up within the study period.

Table 3. Laboratory findings for patients with branch retinal vein occlusion and those with central retinal vein occlusion.

| Reference values | CRVO N (Values) | BRVO N (Values) | \(P\)-value |
|------------------|-----------------|-----------------|-------------|
| ESR 0–26 mm/h    | 92 (13.4 ± 12.9) | 332 (14.1 ± 14.1) | .642*       |
| Homocysteine 4.4–16.2 umol/L | 81 (13.3 ± 6.9) | 320 (11.0 ± 5.2) | .008*       |
| PT 11.5–14.0 s   | 129 (12.2 ± 1.4) | 423 (12.7 ± 2.3) | .004*       |
| aPTT 29.1–45.1 s | 128 (34.6 ± 5.2) | 415 (34.9 ± 4.8) | .534*       |
| BUN 10–26 mg/dL  | 166 (17.5 ± 9.5) | 507 (16.4 ± 7.9) | .176*       |
| Creatinine 0.6–1.2 mg/dL | 166 (1.2 ± 1.5) | 508 (1.0 ± 1.4) | .124*       |
| Albumin 3.8–5.3 g/dL | 163 (4.4 ± 0.4) | 498 (4.4 ± 0.3) | .158*       |
| AST 8–38 IU/L    | 166 (22.4 ± 9.2) | 508 (25.7 ± 15.0) | .001*       |
| ALT 5–43 IU/L    | 166 (20.1 ± 13.4) | 507 (22.6 ± 15.1) | .056*       |
| Gamma GT 11–75 IU/L | 69 (38.5 ± 44.0) | 151 (40.7 ± 51.8) | .769*       |
| Glucose 70–110 mg/dL | 158 (128.0 ± 62.6) | 484 (115.7 ± 43.6) | .023*       |
| Cholesterol 130–200 mg/dL | 163 (188.2 ± 38.6) | 504 (192.1 ± 39.9) | .276*       |
| TG 40–150 mg/dL  | 106 (141.8 ± 89.1) | 354 (152.5 ± 91.8) | .290*       |
| LDL cholesterol 0–130 mg/dL | 103 (116.2 ± 36.4) | 349 (119.8 ± 33.6) | .345*       |
| HDL cholesterol >40 mg/dL | 106 (50.6 ±13.6) | 354 (52.8 ± 13.0) | .125*       |

CRVO: central retinal vein occlusion, BRVO: branch retinal vein occlusion, ESR: erythrocyte sedimentation rate, PT: prothrombin time, aPTT: activated partial thromboplastin time, BUN: blood urea nitrogen, AST: aspartate aminotransferase, ALT: alanine aminotransferase, gamma GT: gamma-glutamyltransferase, TG: triglyceride, LDL: low-density lipoprotein, HDL: high-density lipoprotein

*Independent t-test

https://doi.org/10.1371/journal.pone.0220880.t003

Comparison of systemic conditions at diagnosis between CRVO and BRVO

PLOS ONE | https://doi.org/10.1371/journal.pone.0220880 August 8, 2019 5 / 11
The ratio was significantly higher in patients who were firstly diagnosed with CRVO (\(P < .001\)). However, there were no significant difference between these two groups in terms of age (\(P = .103\)), sex (\(P = .994\)), anthropometric variables, and systemic comorbidities (\(P > .05\) for all).

### Discussion

Risk factors for CRVO and BRVO have been reported by many studies, which have shown some overlap between the two diseases [15, 16]. Nevertheless, not many studies have compared systemic risk factors including laboratory findings for the two types of RVO. In the present study, we investigated differences in systemic conditions, including systemic comorbidities with consideration of laboratory findings, between CRVO and BRVO using a large dataset stored in an electronic CDW system. Compared with the BRVO group, the CRVO group showed male predominance, a higher prevalence of DM and CKD at the time of RVO diagnosis, elevated serum homocysteine levels, and a higher prevalence of abnormal serum BUN/

---

**Table 4. Comparison of complete blood count results between patients with central retinal vein occlusion and those with branch retinal vein occlusion.**

| Unit          | CRVO | Values          | BRVO | Values          | \(P\)-value |
|---------------|------|-----------------|------|-----------------|-------------|
| WBC \(10^3/\mu l\) | 164  | 6.5 ± 2.1       | 488  | 6.6 ± 1.8       | .981*       |
| RBC \(10^3/\mu L\) | 164  | 4.4 ± 0.6       | 488  | 4.5 ± 0.5       | .070*       |
| Hb \(g/dL\)   | 164  | 13.3 ± 2.0      | 489  | 13.7 ± 1.7      | .025*       |
| Hct \(\%\)    | 164  | 39.3 ± 5.4      | 487  | 40.4 ± 4.6      | .026*       |
| Platelet \(10^3/\mu l\) | 164  | 241.7 ± 62.9    | 487  | 244.9 ±67.2     | .595*       |
| Neutrophil \(10^9/L\) | 158  | 4.0 ± 1.8       | 471  | 3.8 ± 1.5       | .158*       |
| Lymphocyte \(10^9/L\) | 80   | 1.8 ± 0.6       | 158  | 1.9 ± 0.7       | .112*       |
| Neutrophil \(\%\) | 163  | 59.3 ± 9.4      | 487  | 56.8 ± 9.6      | .004*       |
| Lymphocyte \(\%\) | 163  | 29.9 ± 8.0      | 487  | 32.2 ± 8.8      | .003*       |
| Monocyte \(\%\) | 163  | 6.0 ± 1.8       | 487  | 6.0 ± 1.9       | .843*       |
| Eosinophil \(\%\) | 163  | 2.6 ± 2.1       | 487  | 2.8 ± 2.7       | .307*       |
| N/L ratio \(\geq 4.0\) | 80   | 2.4 ± 1.2       | 158  | 2.4 ± 1.9       | .942*       |
| N/L ratio \(\leq .05\) | 8.8% | 9.5%            |       |                 | 1.000b      |

CRVO: central retinal vein occlusion, BRVO: branch retinal vein occlusion, WBC: white blood cell, RBC: red blood cell, Hb: hemoglobin, Hct: hematocrit, N/L ratio: neutrophil to lymphocyte ratio.

*Independent t-test
bPearson’s chi-square test

https://doi.org/10.1371/journal.pone.0220880.t004

---

**Table 5. The proportion of subjects with abnormal test results in patients with central retinal vein occlusion and those with branch retinal vein occlusion.**

|                      | CRVO | BRVO | \(P\)-value\(^a\) |
|----------------------|------|------|-------------------|
| Homocysteine \(>16.2\ \text{umol/L}\) | 23.5% | 8.4%  | .000              |
| PT \(>14\ \text{s}\)              | 7.0%  | 5.2%  | .583              |
| AST \(>38\ \text{IU/L}\)         | 6.0%  | 7.9%  | .536              |
| Glucose \(>110\ \text{mg/dL}\)   | 41.8% | 34.9% | .145              |
| BUN \(>26\ \text{mg/dL}\)        | 12.0% | 4.7%  | .002              |
| Creatinine \(>1.2\ \text{mg/dL}\) | 13.3% | 5.5%  | .002              |

CRVO: central retinal vein occlusion, BRVO: branch retinal vein occlusion, PT: prothrombin time, AST: aspartate aminotransferase, BUN: blood urea nitrogen

\(^a\)Chi-square test

https://doi.org/10.1371/journal.pone.0220880.t005
creatinine levels. Although AST levels were significantly different between the BRVO group and the CRVO group, the proportion with AST levels that were abnormal was the same in each type of RVO.

In the Beaver Dam Eye Study, the prevalence and incidence of RVO were similar in men and women; however, there was a trend for female predominance, with an RVO incidence and prevalence of 55.7% and 56.4%, respectively, in women [1]. In the Korean population, the incidence of RVO is 1.28 times higher in women than in men, with the female-to-male ratio for the RVO incidence showing a rapid increase after middle age [17]. Park et al suggested that this change could be closely related to menopausal transition, although they did not perform detailed analyses according to the type of RVO [17]. In the current study, the BRVO group showed female predominance (55%), as observed in previous studies [1, 17], while the CRVO group showed slight male predominance (52%). Although the reason for the latter finding is not clear, we speculate that systemic conditions other than sex may have influenced CRVO development. Genetic and environmental differences between men and women may also have influenced the results.

As observed in previous studies, hypertension was the most common underlying disease in RVO patients in the present study, followed by DM, gastric ulcer, dyslipidemia, and stroke. A strong relationship between RVO and cardiovascular diseases has been reported over the years. Many researchers have found a significantly higher prevalence of hypertension in RVO patients [18–20], along with an increased risk of stroke, atrial fibrillation, and acute myocardial infarction after RVO occurrence [21–23]. A recent meta-analysis of published studies suggested that 48% of RVO cases can be attributed to hypertension, 20% to hyperlipidemia, and 5% to diabetes [24]. Of note, Hayreh et al reported that a higher prevalence of hypertension was observed in BRVO patients than in CRVO and hemi-CRVO patients [8]. They suggested that arteriosclerotic changes in the retinal arteries may play a role in the development of BRVO, but not CRVO, and there was no detailed analysis with SBP and DBP [8]. In the present study, the prevalence of hypertension was similar in both groups, although patients with BRVO showed significantly higher DBP (by 7 mmHg) than did those with CRVO. With this finding, we could assume that atherosclerotic change caused by underlying hypertension in the artery might result in a narrowing of the neighboring venous lumen in both BRVO and CRVO and diastolic arterial hypertension might influence to a greater extent the arteriovenous crossing than the lamina cribrosa where CRVO occurs; however, the role of hypertension in the pathogenesis of CRVO remains to be elucidated [15].

The prevalence of DM and the blood glucose level were significantly higher in patients with CRVO than in those with BRVO in the present study. While some previous studies on RVO did not find a difference in the prevalence of DM between CRVO and BRVO, they found a difference between ischemic and non-ischemic CRVO [8]. The multicenter Eye Disease Case-Control Study Group reported an increased risk of arterial hypertension and cardiovascular disease in BRVO and CRVO patients, with the latter also showing a high risk of DM [18, 19]. These results favor the association of DM with RVO in the present study. Although we could not elucidate the exact cause, the vascular changes in diabetic patients may influence CRVO development. Further studies may be necessary.

The CKD prevalence was higher in the CRVO group than in the BRVO group in the present study. In a previous study, chronic renal failure was observed in 4.9% of patients with ischemic CRVO and in 1.6% of patients with BRVO [8]; these findings were very similar to ours (4.3% in CRVO and 1.8% in BRVO). Another study also claimed that the prevalence of chronic renal failure was significantly higher in CRVO patients than in BRVO patients (15.6% vs. 11.9%; \( P < .0001 \)) [23]. The role of CKD in RVO pathogenesis has not been widely reported; the influence of CKD on retinal vessels was suggested in the setting of diabetic
It has been postulated that circulating toxins and excitotoxic metabolites in the setting of renal insufficiency cause retinal microvascular damage in diabetic retinopathy. Oxidative stress and elevated nitric oxide levels in the bloodstream catalyze endothelial and neuronal damage, which has been noted in cardiorenal syndromes. Since there was significantly higher prevalence of abnormal serum BUN and creatinine levels in the CRVO than in the BRVO group, circulating toxins observed in CKD patients could have caused persistent endothelial damage and could have resulted in CRVO development. Alternatively, arterial hypertension resulted from CKD might play a role in the development of RVO. Whether either, both, or none of the mechanisms suggested above caused the development of RVO, the correlation of CKD with the development of RVO warrants further study.

An interesting finding in the present study is the elevated serum homocysteine level in the CRVO group. Elevated plasma homocysteine is a known risk factor for arterial and venous thrombosis [27]. The mechanisms by which homocysteine damages the blood vessel wall seem to be multifactorial [28, 29]. With regard to the pathogenesis of RVO, the role of homocysteine remains controversial. Some studies reported significantly higher plasma homocysteine levels in RVO [30–32], while others have failed to reveal any relationship [33, 34]. These discrepancies in findings may be due to the small sample sizes in many of the studies, heterogeneous subject populations, and variations in analysis methods. In this regard, the present study overcomes the limitations of previous studies by including a sufficient number of patients belonging to a single ethnicity and by using identical analysis methods.

PT is a measure of the integrity of the extrinsic and final common pathways of the coagulation cascade, which comprises the tissue factor and factors VII, II, V, and X and fibrinogen. A shorter PT in CRVO than in BRVO may be related to a higher serum homocysteine level in the CRVO patients in our study. Elevated homocysteine levels cause thrombosis via several mechanisms, such as increased tissue factor expression, attenuated anticoagulant processes, enhanced platelet activity, increased thrombin generation, augmented factor V activity, impaired fibrinolytic potential, and vascular injury [35]. The increased serum homocysteine level may have affected tissue factor and factor V expression, thus resulting in a decreased PT.

NLR is an inflammatory marker for diseases related to thrombosis and inflammation. Some studies have shown that high neutrophil levels are associated with a poor prognosis and increased mortality in patients with cardiovascular disease [36–38]. Dursun et al explored the association between NLR and RVO development and found a higher neutrophil count in RVO patients than in normal controls [39]. In the present study, the neutrophil and lymphocyte proportions were higher and lower, respectively, in the CRVO group than in the BRVO group. However, we failed to find significant differences in NLR between the two groups, although there was a trend of increased neutrophils and decreased lymphocytes in the CRVO group compared to the BRVO group.

The serum AST level was significantly different between the two groups in the present study. AST is measured with a liver function test, and higher readings may suggest inflammation of liver cells or the death of some cells due to liver damage. Nevertheless, the mean values were within the normal range in both groups. It may be controversial to use AST as a distinguishing risk factor for BRVO, considering that serum AST levels could be affected by several conditions such as alcohol consumption, certain medications, and hyperlipidemia.

The present study has some limitations. The first and most important limitation is that we could not evaluate the severity of RVO because electrical medical chart or fluorescence angiography findings are not included in the CDW database. Hayreh et al reported systemic diseases associated with six different types of RVO [8]. RVO could be divided into different entities according to the extent of ischemia or involved area, and each RVO subgroup may exhibit different clinical characteristics. However, the extensive subgrouping, which resulted in few
subjects per subgroup, could have affected the statistical results. Larger samples with simple grouping and analysis accompanied by laboratory findings could overcome this limitation. Second, it is possible that some patients who had been examined within a different medical system prior to visiting our hospital could have a previous diagnosis of RVO. However, we believe that there were few such cases and did not affect the results. Third, longitudinal analysis with changes in laboratory data or systemic conditions after RVO development and recovery were not evaluated. Nevertheless, to the best of our knowledge, this is thus far one of the largest studies analyzing laboratory data for RVO patients. All patients belonged to a single ethnicity, which minimized genetic differences among the various risk factors. Use of the same analysis method with a single database system (CDW system of HUMC) is another strength of our study.

Our findings suggest that BRVO and CRVO exhibit different systemic conditions at the time of diagnosis. While BRVO may be more common in women, CRVO may be associated with a higher prevalence of DM and CKD as well as increased homocysteine levels and higher prevalence of abnormal serum BUN and creatinine levels. Detailed investigation of risk factors and the severity of RVO, as well as the assessment of changes in laboratory findings during the clinical course, could provide insight into the pathophysiology of RVO and assist in RVO prevention.

Supporting information

S1 File. The demographics and clinical data of the subjects. (XLSX)

S1 Table. Diagnostic criteria for systemic comorbidities. (DOCX)

Author Contributions

Conceptualization: Bum-Joo Cho, Soonil Kwon.
Data curation: So Hyun Bae, Min Chul Shin, In Won Park, Ha Kyoung Kim.
Formal analysis: Sang Min Park.
Funding acquisition: Bum-Joo Cho.
Investigation: Soonil Kwon.
Methodology: In Won Park.
Resources: So Hyun Bae.
Supervision: Sang Min Park, Ha Kyoung Kim.
Validation: Min Chul Shin.
Writing – original draft: Bum-Joo Cho, Soonil Kwon.
Writing – review & editing: Bum-Joo Cho, Sang Min Park, Soonil Kwon.

References

1. Klein R, Klein BE, Moss SE, Meuer SM. The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study. Trans Am Ophthalmol Soc 2000; 98:133–141; discussion 141–133. PMID: 11190017; PubMed Central PMCID: 1298220
2. Ho M, Liu DT, Lam DS, Jonas JB. Retinal Vein Occlusions, from Basics to the Latest Treatment. Retina 2016; 36:432–448. doi: 10.1097/IAE.0000000000000843. PMID: 26716954
3. Hayreh SS. Ocular vascular occlusive disorders: natural history of visual outcome. Prog Retin Eye Res 2014; 41:1–25. doi: 10.1016/j.preteyeres.2014.04.001. PMID: 24769221; PubMed Central PMCID: 4073304

4. Kolar P. Risk factors for central and branch vein occlusion: a meta-analysis of published clinical data. J Ophthalmol 2014; 2014:724780. doi: 10.1155/2014/724780. PMID: 25009743; PubMed Central PMCID: 4070325

5. Koh V, Cheung CY, Li X, Tian D, Wang JJ, Mitchell P, et al. Retinal Vein Occlusion in a Multi-Ethnic Asian Population: The Singapore Epidemiology of Eye Disease Study. Ophthalmic Epidemiol 2016:1–8. doi: 10.3109/09286586.2015.1082604. PMID: 26751637

6. Michalska-Malecka K, Spiewak D, Slowinska-Lozynska L, Sierocka-Stepien J. Influence of hemorhoidal factors on the development of retinal vein occlusion. Clin Hemorheol Microcirc 2016; 63:69–76. doi: 10.3233/CH-162056. PMID: 27163689

7. Yau JW, Lee P, Wong TY, Best J, Jenkins A. Retinal vein occlusion: an approach to diagnosis, systemic risk factors and management. Intern Med J 2008; 38:904–910. doi: 10.1111/j.1445-5994.2008.01720.x. PMID: 19120547

8. Hayreh SS, Zimmerman B, McCarthy MJ, Podhajsky P. Systemic diseases associated with various types of retinal vein occlusion. Am J Ophthalmol 2001; 131:61–77. https://doi.org/10.1016/s0002-9394(01)00709-1 PMID: 11162981

9. Pont KA, Elbaz H, Peto T, Laubert-Reh D, Binder H, Wild PS, et al. Prevalence and risk factors of retinal vein occlusion: the Gutenberg Health Study. J Thromb Haemost 2015; 13:1254–1263. doi: 10.1111/jth.12982. PMID: 25894549

10. Sinawat S, Bunyavee C, Ratanapakorn T, Sinawat S, Laovirojnakul W, Yospaiboon Y. Systemic abnormalities associated with retinal vein occlusion in young patients. Clin Ophthalmol 2017; 11:441–447. doi: 10.2147/OPHT.S128341. PMID: 28260858; PubMed Central PMCID: 5283202

11. Incorvaia C, Parmeggiani F, Costagliola C, Lamberti G, Ferraresi P, Bernardi F, et al. The heterozygous 20210 G/A genotype prevalence in patients affected by central and branch retinal vein occlusion: a pilot study. Graefes Arch Clin Exp Ophthalmol 2001; 239:251–256. PMID: 11450488

12. Hayreh SS, Zimmerman MB, Podhajsky P. Hematologic abnormalities associated with various types of retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2002; 240:180–196. doi: 10.1007/s00417-001-0421-3. PMID: 11935275

13. Chelico JD, Wilcox AB, Vawdrey DK, Kuperman GJ. Designing a Clinical Data Warehouse Architecture to Support Quality Improvement Initiatives. AMIA Annu Symp Proc 2016; 2016:381–390. PMID: 28269833; PubMed Central PMCID: 5333328

14. Lee SH, Lee JJ, Kwon Y, Kim JH, Sohn JH. Clinical Implications of Associations between Headache and Gastrointestinal Disorders: A Study Using the Hallym Smart Clinical Data Warehouse. Front Neurol 2017; 8:526. doi: 10.3389/fneur.2017.00526. PMID: 29042857; PubMed Central PMCID: 5632350

15. Jaulim A, Ahmed B, Khanam T, Chatziralli IP. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature. Retina 2013; 33:901–910. doi: 10.1097/IAE.0b013e3182870c15. PMID: 23609064

16. McAllister IL. Central retinal vein occlusion: a review. Clin Experiment Ophthalmol 2012; 40:48–58. doi: 10.1111/j.1442-9071.2011.02713.x. PMID: 22003973

17. Park SJ, Choi NK, Park KH, Woo SJ. Nationwide incidence of clinically diagnosed retinal vein occlusion in Korea, 2008 through 2011: preponderance of women and the impact of aging. Ophthalmology 2014; 121:1274–1280. doi: 10.1016/j.ophtha.2013.12.024. PMID: 24491641

18. The Eye Disease Case-control Study Group. Risk factors for central retinal vein occlusion. Arch Ophthalmol 1996; 114:545–554. PMID: 8619763

19. The Eye Disease Case-control Study Group. Risk factors for central retinal vein occlusion. Am J Ophthalmol 1993; 116:286–296. PMID: 8357052

20. Dodson PM, Galton DJ, Winder AF. Retinal vascular abnormalities in the hyperlipidaemias. Trans Ophthalmol Soc U K 1981; 101:17–21. PMID: 6964227

21. Rim TH, Kim DW, Han JS, Chung EJ. Retinal vein occlusion and the risk of stroke development: a 9-year nationwide population-based study. Ophthalmology 2015; 122:1187–1194. doi: 10.1016/j.ophtha.2015.01.020. PMID: 25726093

22. Rim TH, Oh J, Lee CS, Lee SC, Kang SM, Kim SS. Evaluation of the Association Between Retinal Vein Occlusion and the Risk of Atrial Fibrillation Development: A 12-Year, Retrospective Nationwide Cohort Study. Sci Rep 2016; 6:34706. doi: 10.1038/srep34706. PMID: 27819343; PubMed Central PMCID: 5098134

23. Chen YY, Sheu SJ, Hu HY, Chu D, Chou P. Association between retinal vein occlusion and an increased risk of acute myocardial infarction: A nationwide population-based follow-up study. PLoS
 Comparison of systemic conditions at diagnosis between CRVO and BRVO

One 2017; 12:e0184016. doi: 10.1371/journal.pone.0184016. PMID: 28898259; PubMed Central PMCID: 5595302

24. O’Mahoney PR, Wong DT, Ray JG. Retinal vein occlusion and traditional risk factors for atherosclerosis. Arch Ophthalmol 2008; 126:692–699. doi: 10.1001/archophthalm.126.5.692. PMID: 18474782

25. Saxena S, Ruia S, Prasad S, Jain A, Mishra N, Natu SM, et al. INCREASED SERUM LEVELS OF UREA AND CREATININE ARE SURROGATE MARKERS FOR DISRUPTION OF RETINAL PHOTORECEPTOR EXTERNAL LIMITING MEMBRANE AND INNER SEGMENT ELLIPSOID ZONE IN TYPE 2 DIABETES MELLITUS. Retina 2017; 37:344–349. doi: 10.1097/IAE.0000000000001163. PMID: 28118284

26. Srivastav K, Saxena S, Mahdi AA, Kruzliak P, Khanna VK. Increased serum urea and creatinine levels correlate with decreased retinal nerve fibre layer thickness in diabetic retinopathy. Biomarkers 2015; 20:470–473. doi: 10.3109/1354750X.2015.1094142. PMID: 26474118

27. Lentz SR. Mechanisms of homocysteine-induced atherothrombosis. J Thromb Haemost 2005; 3:1646–1654. doi: 10.1111/j.1538-7836.2005.01364.x. PMID: 16102030

28. Jakubowski H. Pathophysiological consequences of homocysteine excess. J Nutr 2006; 136:1741s–1749s. https://doi.org/10.1093/jn/136.6.1741S PMID: 16702349

29. Weiss N. Mechanisms of increased vascular oxidant stress in hyperhomocysteinaemia and its impact on endothelial function. Curr Drug Metab 2005; 6:27–36. PMID: 15720205

30. Chua B, Kifley A, Wong TY, Mitchell P. Homocysteine and retinal vein occlusion: a population-based study. Am J Ophthalmol 2005; 139:181–182. doi: 10.1016/j.ajo.2004.06.084. PMID: 15652845

31. Vine AK. Hyperhomocysteinaemia: a risk factor for central retinal vein occlusion. Am J Ophthalmol 2000; 129:640–644. https://doi.org/10.1016/s0002-9394(99)00476-6 PMID: 10844057

32. Brown BA, Marx JL, Ward TP, Hollifield RD, Dick JS, Brozetti JJ, et al. Homocysteine: a risk factor for retinal venous occlusive disease. Ophthalmology 2002; 109:287–290. https://doi.org/10.1016/s0161-6420(01)00476-6 PMID: 11825810

33. Pinna A, Carru C, Zinelli A, Dore S, Deiana L, Carta F. Plasma homocysteine and cysteine levels in retinal vein occlusion. Invest Ophthalmol Vis Sci 2006; 47:4067–4071. doi: 10.1167/iovs.06-0290. PMID: 16938125

34. Mcgimpsey SJ, Woodsie JV, Cardwell C, Cahill M, Chakravarthy U. Homocysteine, methylenetetrahydrofolate reductase C677T polymorphism, and risk of retinal vein occlusion: a meta-analysis. Ophthalmology 2009; 116:1778–1787.e1771. doi: 10.1016/j.ophtha.2009.02.033. PMID: 19729099

35. Undas A, Brozek J, Szczeklik A. Homocysteine and thrombosis: from basic science to clinical evidence. Thromb Haemost 2005; 94:907–915. doi: 10.1160/TH05-05-0313. PMID: 16363230

36. Pellizzon GG, Dixon SR, Stone GW, Cox DA, Mattos L, Boura JA, et al. Relation of admission white blood cell count to long-term outcomes after primary coronary angioplasty for acute myocardial infarction (The Stent PAMI Trial). Am J Cardiol 2003; 91:729–731. https://doi.org/10.1016/s0002-9149(02)03416-1 PMID: 12633810

37. Uthamalingam S, Patvardhan EA, Subramanian S, Ahmed W, Martin W, Daley M, et al. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am J Cardiol 2011; 107:433–438. doi: 10.1016/j.amjcard.2010.09.039. PMID: 21257011

38. Duffy BK, Gurum HS, Rajagopal V, Gupta R, Ellis SG, Bhatt DL. Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention. Am J Cardiol 2006; 97:993–996. doi: 10.1016/j.amjcard.2005.10.034. PMID: 16563903

39. Dursun A, Ozturk S, Yuclu H, Ozcev AC, Dursun FG, Toker MI, et al. Association of neutrophil/lymphocyte ratio and retinal vein occlusion. Eur J Ophthalmol 2015; 25:343–346. doi: 10.5301/ejo.5000570. PMID: 25633622